On Monday, Axsome Therapeutics earned a positive adjustment to its Relative Strength (RS) Rating, from 67 to 73.
IBD's proprietary rating identifies share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
History shows that the market's biggest winners typically have an 80 or better RS Rating as they begin their largest climbs. See if Axsome Therapeutics can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Axsome Therapeutics is building a cup with handle with a 97.00 entry. See if the stock can clear the breakout price in volume at least 40% above average.
Axsome Therapeutics posted 0% EPS growth in the latest quarterly report. Sales increased 87%. The company is expected to report its latest performance numbers on or around Nov. 12.
The company earns the No. 210 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
